GGHC
ATRC icon

Gilder Gagnon Howe & Co’s AtriCure ATRC Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio ATRC Stock Details ATRC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-47,323
Closed -$1.33M – 257
2024
Q3 		$1.33M Buy
+47,323
New +$1.17M 0.02% 197
2022
Q1 		– Sell
-42
Closed -$3K – 299
2021
Q4 		$3K Hold
42
– – ﹤0.01% 384
2021
Q3 		$3K Hold
42
– – ﹤0.01% 414
2021
Q2 		$3K Hold
42
– – ﹤0.01% 395
2021
Q1 		$3K Hold
42
– – ﹤0.01% 384
2020
Q4 		$2K Sell
42
-337,647
-100% -$14.6M ﹤0.01% 334
2020
Q3 		$13.5M Sell
337,689
-695,661
-67% -$29.5M 0.08% 154
2020
Q2 		$46.4M Buy
+1,033,350
New +$45M 0.36% 81

Other funds holding ATRC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Gilder Gagnon Howe & Co's ATRC Position: Q4 2024 in Review

Gilder Gagnon Howe & Co sold out of AtriCure (ATRC) in Q4 2024, closing a stake of 47,323 shares — an estimated $1.33M sold.

Gilder Gagnon Howe & Co first reported a position in ATRC in Q2 2020 and held it in 8 quarters. The position peaked at $46.4M in Q2 2020. 213 funds tracked by Wall St. Rank hold ATRC as of Q4 2024.

  • Gilder Gagnon Howe & Co reported no remaining AtriCure position as of Q4 2024 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 47,323 AtriCure shares in Q4 2024, an estimated $1.33M.
  • Gilder Gagnon Howe & Co first reported a position in AtriCure in Q2 2020 and held it in 8 quarters.
  • Gilder Gagnon Howe & Co's AtriCure position peaked at $46.4M in Q2 2020.
  • 213 funds tracked by Wall St. Rank held AtriCure as of Q4 2024.

Based on Gilder Gagnon Howe & Co's 13F filing for Q4 2024, filed 14 Feb 2025.